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Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD) and 
is associated with an excessively high risk for death and amputation of the affected 
extremity.1 The clinical hallmarks of CLI are rest pain and tissue loss due to progressive 
occlusion of the arteries in the leg as a result of atherosclerosis and less frequently, 
autoimmune and inflammatory disorders.2 The estimated annual incidence of CLI in 
Western society is 500 to 1,000 new cases which is expected to increase as the population 
ages and obesity and diabetes become more prevalent.3 Treatment strategies for CLI have 
traditionally focused on surgical bypass or endovascular interventions that improve limb 
perfusion to prevent amputation of the affected leg. Unfortunately 40% of patients with CLI 
will not have options for these procedures and as a result over 53,000 amputations are 
performed annually in the U.S. and patients with diabetes, Rutherford class 5 or 6 disease 
(tissue loss), and renal dysfunction at highest risk for limb loss.3,4
Over the past decade there has been an avid interest in cell-based therapies to promote 
neovascularization and enhance limb perfusion as a strategy to prevent amputation in this 
“no option” CLI population. Multiple studies have suggested that autologous cells derived 
from both bone marrow and peripheral blood may decrease amputation rates however these 
studies had small sample sizes, lacked control groups, and end-points were ill defined. To 
decipher these varied results the current report in Circulation Research by Rigato et al5 
provides a meta-analysis of all published trials in the last decade using autologous cell 
therapy treat CLI. Within, the authors describe analysis of 19 randomized controlled trials 
(RCTs; 837 patients), 7 non-randomized trials (338 patients), and 41 non-controlled studies 
(1177 patients). Although heterogeneity was high and publication bias could not be 
excluded, an improvement of 18% was found in amputation free survival (AFS), a composite 
measure of all cause mortality and major amputation (defined as above the ankle), compared 
to controls. Additional improvements were noted in amputation risk reduction (37%), wound 
healing (59%), ABI, TcPO2, walking capacity, and rest pain index.
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As with any meta-analysis, accumulation of homogeneous data can be a significant 
challenge. In this paper, the authors report 67 total accumulated reports of various designs. 
The majority of the reports were non-controlled studies (61%) which spanned 50% of the 
total number of patients included. Further compromising the ability of this analysis to assess 
efficacy of autologous cell therapy is that the studies included in the review represented a 
wide clinical spectrum of patients ranging from mild claudicants to severe CLI. The 
treatment vehicles also consisted of a combination of bone marrow and peripherally derived 
stem cells administered intravenously, intramuscularly, or both. The final observations 
reached by the authors, that little to no difference in preventing amputation is observed 
between placebo and cell therapy in the high-quality,placebo-controlled RCTs demonstrate a 
very strong inverse relationship is observed between quality of evidence and therapeutic 
effect, revealing the ambiguity and confusion that poorly designed trials create, specifically 
in CLI. Further limitations in this analysis is the inability to compare results based on critical 
variables that determine limb loss in CLI, diabetes, renal function, and Rutherford class.4 
Thus there is an imperative need for well designed, randomized, placebo controlled trials to 
provide pivotal data regarding the efficacy of autologous cell therapy in CLI.
Since this report by Rigato and colleagues we have completed the Phase III multi-center 
randomized, placebo-controlled Marrowstim Treatment of Limb IschemIa in Subjects With 
Severe Peripheral ArteriaL DiseasE (MOBILE) Trial (NCT01049919). From May 2010 to 
May 2015, 152 patients (M 88, F 64) were enrolled at 24 centers in the U.S. and randomized 
in a 3:1 fashion to autologous concentrated bone marrow cells (cBMA) or placebo (sham 
procedure), respectively. Although patients with renal failure or significant dysfunction were 
excluded, randomization was stratified to each study group based on the two second most 
important predictors of amputation in CLI, diabetes and Rutherford class(4- rest pain; 5-
minor tissue loss). The primary clinical endpoint was amputation free survival at 52 weeks. 
We found that there was a numerical improvement in AFS in the cBMA group at 52 weeks 
however this was not significant (79.8 vs 69.5%), HR (95% CI) = 0.64 (0.31-1.31), P= 0.22 
(unpublished data). However on post-hoc analyses when Rutherford 5 (tissue loss) diabetics 
were excluded AFS was significantly greater in the cBMA group compared to placebo at 52 
weeks (86.2 vs. 66.7%, HR(CI)=0.37 (0.16-0.85), P=0.018. These initial results coupled 
with the findings of Rigato5 et al critically highlight the importance of randomized placebo 
controlled trials in CLI.
In conclusion, there is accumulating evidence the autologous cell therapy provides benefit in 
preventing amputation in select patients with CLI.Future studies need to be stratified based 
on key variables that determine outcomes in this heterogenous patient population and should 
focus on potentially more potent cell sources.
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